New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With Breziri in COPD
May 24, 2023
May 24, 2023
WILMINGTON, Delaware, May 24 -- AstraZeneca, a biopharmaceutical company, issued the following news release on May 23, 2023:
EROS real-world outcomes data show prompt initiation of BREZTRI is associated with a reduced risk of future exacerbations in people living with COPD/1
EXACOS-CV US data highlights increased risk of severe cardiovascular events following an acute COPD exacerbation./2
Results from the EROS real-world retrospective study showed that init . . .
EROS real-world outcomes data show prompt initiation of BREZTRI is associated with a reduced risk of future exacerbations in people living with COPD/1
EXACOS-CV US data highlights increased risk of severe cardiovascular events following an acute COPD exacerbation./2
Results from the EROS real-world retrospective study showed that init . . .